RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter
Date
2016-08-24
RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter
FDA Accepts Phase 3 Design Based on Results from Previous Phase 2b/3 Dry Eye Trial
(if you want to view the body of article, click on the bottom link)
http://www.prnewswire.com/news-releases/regenerx-joint-venture-to-begin-second-phase-3-study-of-rgn-259-for-dry-eye-syndrome-in-3rd-quarter-300317206.html
FDA Accepts Phase 3 Design Based on Results from Previous Phase 2b/3 Dry Eye Trial
(if you want to view the body of article, click on the bottom link)
http://www.prnewswire.com/news-releases/regenerx-joint-venture-to-begin-second-phase-3-study-of-rgn-259-for-dry-eye-syndrome-in-3rd-quarter-300317206.html